Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses

P. J. Keith, D. A. Wetter, J. W. Wilson, Julia Lehman

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Autoimmune bullous dermatoses (ABD) compromise the skin's innate barrier function for preventing infection. Treating patients with ABD frequently requires systemic immunosuppressive therapy, often with multiple agents. Currently, no pretreatment infection testing guidelines are available for clinicians caring for patients with ABD. We performed a systematic literature review in other medical disciplines that use similar iatrogenic immunosuppressive medications to treat various diseases and conditions and developed infection-testing recommendations for patients with ABD before initiating immunosuppressive therapy. Assessing individual patient risk factors for latent infection and preventable communicable diseases can direct testing for select infections before starting immunosuppressive therapy. Testing patients for hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis infection is recommended before initiating rituximab treatment. What's already known about this topic? Iatrogenic immunosuppressive therapy increases the risk of infection in patients with autoimmune bullous dermatoses (ABD). Infections are a common cause of morbidity and mortality in patients with ABD. What does this study add? Assessment of infection risk before initiating iatrogenic immunosuppression, on the basis of pre-existing guidelines, is important to prevent infection-associated morbidity and mortality in this unique patient population. We provide evidence-based laboratory screening recommendations for patients with ABD.

Original languageEnglish (US)
Pages (from-to)1307-1317
Number of pages11
JournalBritish Journal of Dermatology
Volume171
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Vesiculobullous Skin Diseases
Immunosuppressive Agents
Communicable Diseases
Guidelines
Infection
Morbidity
Therapeutics
Mycobacterium Infections
Mortality
Mycobacterium tuberculosis
Hepatitis B virus
Hepacivirus
Immunosuppression

ASJC Scopus subject areas

  • Dermatology

Cite this

Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. / Keith, P. J.; Wetter, D. A.; Wilson, J. W.; Lehman, Julia.

In: British Journal of Dermatology, Vol. 171, No. 6, 01.01.2014, p. 1307-1317.

Research output: Contribution to journalReview article

@article{678b69c56fa54dca810f19e20be9991d,
title = "Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses",
abstract = "Autoimmune bullous dermatoses (ABD) compromise the skin's innate barrier function for preventing infection. Treating patients with ABD frequently requires systemic immunosuppressive therapy, often with multiple agents. Currently, no pretreatment infection testing guidelines are available for clinicians caring for patients with ABD. We performed a systematic literature review in other medical disciplines that use similar iatrogenic immunosuppressive medications to treat various diseases and conditions and developed infection-testing recommendations for patients with ABD before initiating immunosuppressive therapy. Assessing individual patient risk factors for latent infection and preventable communicable diseases can direct testing for select infections before starting immunosuppressive therapy. Testing patients for hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis infection is recommended before initiating rituximab treatment. What's already known about this topic? Iatrogenic immunosuppressive therapy increases the risk of infection in patients with autoimmune bullous dermatoses (ABD). Infections are a common cause of morbidity and mortality in patients with ABD. What does this study add? Assessment of infection risk before initiating iatrogenic immunosuppression, on the basis of pre-existing guidelines, is important to prevent infection-associated morbidity and mortality in this unique patient population. We provide evidence-based laboratory screening recommendations for patients with ABD.",
author = "Keith, {P. J.} and Wetter, {D. A.} and Wilson, {J. W.} and Julia Lehman",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/bjd.13355",
language = "English (US)",
volume = "171",
pages = "1307--1317",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses

AU - Keith, P. J.

AU - Wetter, D. A.

AU - Wilson, J. W.

AU - Lehman, Julia

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Autoimmune bullous dermatoses (ABD) compromise the skin's innate barrier function for preventing infection. Treating patients with ABD frequently requires systemic immunosuppressive therapy, often with multiple agents. Currently, no pretreatment infection testing guidelines are available for clinicians caring for patients with ABD. We performed a systematic literature review in other medical disciplines that use similar iatrogenic immunosuppressive medications to treat various diseases and conditions and developed infection-testing recommendations for patients with ABD before initiating immunosuppressive therapy. Assessing individual patient risk factors for latent infection and preventable communicable diseases can direct testing for select infections before starting immunosuppressive therapy. Testing patients for hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis infection is recommended before initiating rituximab treatment. What's already known about this topic? Iatrogenic immunosuppressive therapy increases the risk of infection in patients with autoimmune bullous dermatoses (ABD). Infections are a common cause of morbidity and mortality in patients with ABD. What does this study add? Assessment of infection risk before initiating iatrogenic immunosuppression, on the basis of pre-existing guidelines, is important to prevent infection-associated morbidity and mortality in this unique patient population. We provide evidence-based laboratory screening recommendations for patients with ABD.

AB - Autoimmune bullous dermatoses (ABD) compromise the skin's innate barrier function for preventing infection. Treating patients with ABD frequently requires systemic immunosuppressive therapy, often with multiple agents. Currently, no pretreatment infection testing guidelines are available for clinicians caring for patients with ABD. We performed a systematic literature review in other medical disciplines that use similar iatrogenic immunosuppressive medications to treat various diseases and conditions and developed infection-testing recommendations for patients with ABD before initiating immunosuppressive therapy. Assessing individual patient risk factors for latent infection and preventable communicable diseases can direct testing for select infections before starting immunosuppressive therapy. Testing patients for hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis infection is recommended before initiating rituximab treatment. What's already known about this topic? Iatrogenic immunosuppressive therapy increases the risk of infection in patients with autoimmune bullous dermatoses (ABD). Infections are a common cause of morbidity and mortality in patients with ABD. What does this study add? Assessment of infection risk before initiating iatrogenic immunosuppression, on the basis of pre-existing guidelines, is important to prevent infection-associated morbidity and mortality in this unique patient population. We provide evidence-based laboratory screening recommendations for patients with ABD.

UR - http://www.scopus.com/inward/record.url?scp=84919459654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919459654&partnerID=8YFLogxK

U2 - 10.1111/bjd.13355

DO - 10.1111/bjd.13355

M3 - Review article

C2 - 25130049

AN - SCOPUS:84919459654

VL - 171

SP - 1307

EP - 1317

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -